Regeneron Just Crashed the Rarest Bone Disease Party

The drug also tackled flare-ups, those painful inflammatory episodes that often precede new bone formation. At the higher dose (10 mg/kg), clinician-assessed flare-ups dropped by 88–89% versus placebo. The lower dose showed a smaller reduction on that measure, and patient-reported flare-ups didn't reach statistical significance, which gives the picture some nuance. Still, the headline numbers are hard to argue with.

On safety, the trial was reassuring. Serious side effects were uncommon across all groups, with no deaths reported and no serious bleeding events.

Ipsen's Rough Day Gets Rougher

Sohonos has been Ipsen's lone entry in FOP since 2023, but its reign hasn't exactly been a victory lap. Sales have been, to put it politely, modest. For context, that's the kind of revenue number that makes investor presentations awkward.

Part of the problem is that Sohonos has faced persistent questions about its benefit-risk profile. When you're the only approved option, patients and doctors will try you out. But once a competitor arrives with cleaner data and eye-popping efficacy numbers, the calculus changes fast.

Regeneron's entrance doesn't just add competition; it reframes the entire conversation around what "good" looks like in FOP treatment. A 90%+ reduction in new bone lesions is a high bar, and Ipsen now has to defend market share against that standard.

A $1.4 Million Question

Of course, nothing in ultra-rare disease comes cheap. Regeneron's list price for Pasatru lands at approximately $1.4 million per patient per year. The dosing schedule is 10 mg/kg given intravenously every four weeks, with the option to step down to 3 mg/kg if tolerability is an issue.

That price tag sounds astronomical, but it's par for the course in ultra-orphan diseases where the patient population is measured in hundreds, not millions. Payers are used to these numbers in the rare disease world, and the strength of the OPTIMA data gives Regeneron a solid argument for value.

The real question is whether Regeneron can capture meaningful share from Sohonos and pull in treatment-naive patients at the same time. In a market this small, every patient switch matters enormously.

The Bigger Picture for Regeneron

Regenrons is mostly known for Dupixent (the atopic dermatitis and asthma blockbuster) and Eylea (its eye-disease juggernaut). FOP is a much smaller stage, but it fits a deliberate pattern. The company has been steadily building out its rare disease portfolio, positioning itself as a player willing to invest decades of basic science into niche indications.

Garetosmab's journey from Activin A biology to FDA approval represents one of those cases where deep mechanistic understanding actually paid off commercially. Regeneron has even shown preclinical data suggesting that blocking Activin A can prevent rogue bone from regrowing after surgical removal, hinting at future label expansions or combination strategies.

FOP may never be a billion-dollar franchise on its own. But for a company trying to prove it can translate rare-disease biology into real therapies, Pasatru is a compelling proof of concept.

What This Means for Patients

For the FOP community, this approval is genuinely meaningful. Going from one option to two isn't just about market competition; it's about choice. Different patients respond differently to treatments, tolerate different side effects, and have different preferences about dosing and delivery.

Having a second approved therapy with strong Phase 3 data gives doctors a real alternative, and it gives patients leverage. When there's only one drug on the menu, you eat what's served. When there are two, the menu works for you.

Regenrons didn't just get an FDA approval. It gave one of the most underserved patient communities in medicine something they haven't had before: options.

Arsenal Bio Just Torched Its Own Playbook. Here's Why.

Arsenal Biosciences just fired 99 employees, killed its clinical programs, and bet everything on a technology that barely exists in the clinic. When a company backed by $630 million torches its own playbook, it tells you something important about where cell therapy is headed.